Company intelligence / Profile preview

Asia Cell Therapeutics

Ownership: Private
Development stage: Phase 1

Overview

Currently conducting Phase I clinical trials for burns & COPD treatments, and Phase II clinical trials for ankylosing spondylitis, liver cirrhosis & acute respiratory distress disorder. Received positive pre-IND responses from FDA for AS treatment. Planning to apply for IND to China NMPA and/or US FDA from 2025 Q1 for iPSC-derived cell therapeutic products.

Therapeutic areas: GastroenterologyPulmonologyDermatologyRheumatology
Modalities: Cell therapyGene therapyStem cell therapy
Industry: Biotech

Drug pipeline

2 assets

aCell Inj.

Unknown

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Asia Cell Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asia Cell Therapeutics.